Back
covid-19 News
1 min de lecture

[Press information] XENOTHERA announces the continuation of development of its anti-SARS-CoV-2 antibody.

  • contact@xenothera.com
  • Auteur
    contact@xenothera.com
  • Publié
    11 mars 2022

Articles récents

[Press Release] XENOTHERA recruits the first patient in the clinical trial of XON7, its new anti-cancer treatment

November 27, 2023. # Download our press release (english version) # Télécharger...

More

[Press Release] French biotech announces its therapeutic potential for oxygen-free patients

October 25, 2023. # Download our press release (english version) # Télécharger...

More

[Press Release] New hope for patients: XENOTHERA granted orphan drug designation (ODD ) from the FDA for LIS1 in the treatment of T-lymphomas.

September 12, 2023. # Download our press release (english version) # Télécharger...

More